Figure 5.
PI3K-engaged PDGFRα signaling mediates cell survival and proliferation in primary MEPM cells. (A) Cell growth as assessed by crystal violet staining in E13.5 primary MEPM cells grown in medium containing 10% FBS and treated once with LY294002 or H2O2 and/or daily with PDGF-AA for up to 4 d. MEPM cell survival is impaired in the presence of the PI3K inhibitor LY294002 (64.88% ± 1.538% decrease in relative absorbance; P = 0.0130) regardless of PDGF-AA ligand stimulation (68.48% ± 0.2966% decrease in relative absorbance; P = 0.0197). PDGF-AA treatment provides protection from hydrogen peroxide-induced apoptosis (54.88% ± 26.34% increase in relative absorbance; P = 0.1653). (B) Cell growth as assessed by crystal violet staining in Pdgfra+/+- and PdgfraPI3K/PI3K-derived E13.5 primary MEPM cells grown in medium containing 10% or 0.1% FBS and treated with PDGF-AA for 1 d. PdgfraPI3K/PI3K-derived MEPM cells under serum starvation conditions do not proliferate in response to PDGF-AA treatment. Data are presented as mean ± SEM.